Orexo reaches principal agreement to settle US Department of Justice investigation
Orexo AB has announced a non-binding agreement in principle with the US Department of Justice (DOJ). The agreement addresses the main elements of an investigation that began in February 2020.
Uppsala, Sweden – August 31, 2026 – Pharmaceutical company Orexo AB announced it has reached a non-binding agreement in principle with the US Department of Justice (DOJ). The agreement is intended to resolve an investigation that commenced in February 2020 concerning the company's activities.
Orexo stated that settlement negotiations are in their final stages, with the definitive settlement agreement currently being finalized. However, the company cannot provide assurance that a final settlement will be entered into on the agreed-upon terms.
Further details regarding the nature of the investigation or the specific terms of the settlement have not yet been disclosed. The company expects to provide further updates once a definitive agreement is executed or negotiations conclude otherwise.
The company's primary focus is on developing and commercializing medicines for addiction treatment and pain management. Orexo's operations in the United States represent a significant component of its global business.